Reason for request
Inclusion
Clinical Benefit
| Substantial |
Substantial actual benefit |
Clinical Added Value
| important |
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation. |
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
bzE1KGuc49Red2zH
